Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can better detection of precancerous lesions in IBD prevent colorectal cancer?

NCT ID NCT07719426

Knowledge-focused Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

People with inflammatory bowel disease (Crohn's disease or ulcerative colitis) have a higher risk of developing colorectal cancer. This study follows 800 adults with IBD who need a screening colonoscopy to look for precancerous growths called dysplasia. Researchers aim to understand how common these lesions are, how they look under high-definition endoscopy, and how often they return after removal. The goal is to improve screening and treatment strategies to lower cancer risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better guidelines for detecting and treating precancerous lesions in IBD patients, potentially reducing colorectal cancer risk.
What could go wrong
This is an observational study, so it does not test a new treatment. Results may not change current practice if the findings are inconclusive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All IBD patients requiring colonoscopy for screening or treatment of dysplasia are eligible for inclusion. All consecutive patients from selected centers meeting the inclusion criteria will be included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients age ≥ 18 years * Documented diagnosis of CD or UC established based on standard clinical, endoscopic and histological criteria. * IBD patients requiring screening colonoscopy for dysplasia as following: * IBD (CD/UC) evolving for more than 8 years, or for ≥1 year if associated with Primary Sclerosing Cholangitis (PSC) * For UC: Extended ulcerative colitis (E2 or E3 in the Montreal classification) * For CD: Colonic (L2) or ileocolonic (L3) Crohn's disease with \> 50% involvement of the colon. * Patient affiliated to the health security system * Patient who has received information about the study by the investigator and agreed to participate. Exclusion Criteria: * Patient followed for ileal Crohn's disease (L1) * Patient followed for rectal ulcerative colitis (E1) * Patient referred for a therapeutic endoscopic procedure, without prior or subsequent follow-up in the participating center * Patients \< 18 years old * Patient under guardianship or curatorship * Patient objects to their personal data being used in the context of research

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colitis ulcerative are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colitis ulcerative Crohn disease (CD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.